key: cord-0883197-s1dert6n authors: Abu-Raddad, L. J.; Chemaitelly, H.; Coyle, P.; Malek, J. A.; Ahmed, A. A.; Mohamoud, Y. A.; Younuskunju, S.; Ayoub, H. H.; Al Kanaani, Z.; Al Kuwari, E.; Butt, A. A.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul Rahim, H. F.; Nasrallah, G. K.; Yassine, H. M.; Al Kuwari, M. G.; Al Romaihi, H. E.; Al-Thani, M. H.; Al Khal, A.; Bertollini, R. title: SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks date: 2021-01-15 journal: nan DOI: 10.1101/2021.01.15.21249731 sha: 06fb820a2d4b10f11ba2cfa432a58883cf6e2fa3 doc_id: 883197 cord_uid: s1dert6n Background: Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. Risk and incidence rate of SARS-CoV-2 reinfection were assessed in a large cohort of antibody-positive persons in Qatar. Methods: All SARS-CoV-2 antibody-positive persons with a PCR-positive swab [≥]14 days after the first-positive antibody test were individually investigated for evidence of reinfection. Viral genome sequencing was conducted for paired viral specimens to confirm reinfection. Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab [≥]14 days after the first-positive antibody test. Of these individuals, 129 (41.1%) had supporting epidemiological evidence for reinfection. Reinfection was next investigated using viral genome sequencing. Applying the viral-genome-sequencing confirmation rate, the risk of reinfection was estimated at 0.10% (95% CI: 0.08-0.11%). The incidence rate of reinfection was estimated at 0.66 per 10,000 person-weeks (95% CI: 0.56-0.78). Incidence rate of reinfection versus month of follow-up did not show any evidence of waning of immunity for over seven months of follow-up. Efficacy of natural infection against reinfection was estimated at >90%. Reinfections were less severe than primary infections. Only one reinfection was severe, two were moderate, and none were critical or fatal. Most reinfections (66.7%) were diagnosed incidentally through random or routine testing, or through contact tracing. Conclusions: Reinfection is rare. Natural infection appears to elicit strong protection against reinfection with an efficacy >90% for at least seven months. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused extensive disease and death, with heavy social and economic losses [1] [2] [3] [4] . In addition to the risk of first infection, reinfection during this prolonged pandemic has raised additional public health concerns [5] [6] [7] [8] [9] . We recently assessed the risk and incidence rate of documented reinfection in a cohort of 130,266 SARS-CoV-2 polymerase chain reaction (PCR)-confirmed infected persons in Qatar [5] , a country of 2.8 million population [10, 11] that experienced a large SARS-CoV-2 epidemic [12] [13] [14] [15] [16] . Benefiting from a centralized data-capture system for nationwide SARS-CoV-2 PCR testing and using viral genome sequencing, we quantified the risk of reinfection at ~2 reinfections per 10,000 infected persons [5] . Incidence rate of reinfection was estimated at 0.36 (95% CI: 0.28-0.47) per 10,000 person-weeks [5] . Serological testing for SARS-CoV-2 infection has been expanding in Qatar during the last few months [14, 16, 17] . The objective of the present study was to quantify the risk and incidence rate of documented reinfection in a cohort of 43,044 persons who had a laboratory-confirmed, anti-SARS-CoV-2 positive result, regardless of whether these persons had ever had a diagnosed PCR-confirmed infection. Persons with a PCR-confirmed infection could, in principle, be biologically different from persons with an antibody-confirmed infection, as the former population is more likely to have experienced symptomatic or even serious primary infection, while the latter population is more likely to have experienced an asymptomatic or mild primary infection that may never have been diagnosed. Moreover, some of those with PCR-confirmed infection may not have developed detectable antibodies [5, 7] . Antibodies against SARS-CoV-2 in serological samples were detected using the Roche Elecsys ® Anti-SARS-CoV-2 assay (Roche, Switzerland), an electrochemiluminescence immunoassay that uses a recombinant protein representing the nucleocapsid (N) antigen for antibody binding. Results were interpreted according to the manufacturer's instructions (reactive: optical density (antibody titer) cutoff index ≥1.0 vs. non-reactive: optical density cutoff index <1.0). Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on the QIAsymphony platform (QIAGEN, USA) and tested with real-time reversetranscription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on ABI 7500 FAST (Thermo Fisher, USA). Samples were extracted using a custom protocol [24] on a Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kit (Bioneer, Korea) on ABI 7500 FAST, or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab regions. The second targets the virus' RdRp and E-gene regions, and the third targets the ORF1ab and E-gene regions. All testing was conducted at HMC Central Laboratory or at Sidra Medicine Laboratory, following standardized protocols. All SARS-CoV-2 antibody-positive persons in Qatar with at least one PCR-positive swab that occurred ≥14 days after the first-positive antibody test were considered as suspected cases of reinfection. These were classified as showing either good evidence, some evidence, or weak (or no) evidence for reinfection based on criteria applied to each case (Box 1). We defined the reinfection swab as the first-positive PCR swab that was identified ≥14 days after the firstpositive antibody test. The 14-day cutoff was incorporated to exclude cases in which antibody testing and PCR testing were done around the same time as part of clinical care of COVID-19 patients-a PCR-positive swab within few days of an antibody-positive test is likely to reflect active primary infection under clinical consideration rather than a reinfection. Suspected reinfection cases with a PCR cycle threshold (Ct) value ≤30 for the reinfection swab (suggestive of a recent active infection) [25] [26] [27] and who had not had a PCR-positive swab for 45 days preceding the reinfection swab (to rule out persisting PCR positivity due to non-viable virus fragments) [5, 25, [28] [29] [30] , were considered as showing good evidence for reinfection. Suspected reinfection cases who had not had a PCR-positive swab for 45 days preceding the reinfection swab, but whose Ct value for the reinfection swab was >30, were considered as showing some evidence for reinfection. Suspected reinfection cases who had a PCR-positive swab within the 45 days preceding the reinfection swab were considered as showing weak (or no) evidence for reinfection, as they are likely to reflect prolonged PCR positivity of the primary infection rather than a reinfection [5, 25, [28] [29] [30] . For a subset of investigated reinfection cases with good or some evidence for reinfection, there were records indicating prior diagnosis of the primary infection. Viral genome sequencing was thus conducted to confirm reinfection in this subset of cases whenever it was possible to retrieve All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249731 doi: medRxiv preprint both, the first-infection PCR-positive swab and the reinfection swab. Details of viral genome sequencing methods are provided in Supplementary Text S1. Risk of documented reinfection was assessed by quantifying the proportion of cases with good or some evidence for reinfection among all eligible anti-SARS-CoV-2 positive cases with an antibody-positive test ≥14 days from end-of-study censoring (excluding cases whose residual blood was tested for antibodies after death). Incidence rate of documented reinfection was calculated by dividing the number of cases with good or some evidence for reinfection by the number of person-weeks contributed by all anti-SARS-CoV-2 positive cases. The follow-up person-time was calculated starting 14 days after the first-positive antibody test until the reinfection swab, all-cause death, or end-of-study censoring (set on December 31, 2020). Adjusted estimates for the risk of reinfection and the incidence rate of reinfection were derived by applying the confirmation rate obtained from viral genome sequencing analysis. This study was approved by the HMC and Weill Cornell Medicine-Qatar Institutional Review Boards. The process for selecting suspected cases of SARS-CoV-2 reinfection is shown in Figure 1 , which summarizes results of their reinfection status evaluation. Of 192,984 persons tested for anti-SARS-CoV-2 using blood specimens collected between April 16-December 31, 2020, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. Investigation of these 314 suspected cases of reinfection yielded 32 cases with good evidence for reinfection (Ct ≤30 for reinfection swab), 97 cases with some evidence (Ct >30 for reinfection swab), while evidence was weak for the remaining 185 cases. Characteristics of the 129 cases with good or some evidence for reinfection are shown in Table 1 . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. At the time of the reinfection swab, eight cases had records in the severity database. One of these was classified as "severe" and two as "moderate" per WHO classification [22] , while the other five were classified as "asymptomatic." At time of primary infection, 14 cases had records in the severity database, one of whom was classified as "critical", three as "severe", five as "moderate", two as "mild", and three as "asymptomatic." For the rest of the reinfection cases, no severity classification was conducted because of minimal or no symptoms to warrant a clinical assessment. For the eight asymptomatic cases above that had a severity assessment, the assessment was conducted because of non-COVID-related hospitalization. No deaths were recorded for any of these reinfection cases. Among the 129 cases with good or some evidence for reinfection, 62 had records indicating prior diagnosis of a primary infection. Paired specimens of the first-infection PCR-positive swab and the reinfection swab were retrieved in 23 cases. Viral genome sequencing results are summarized in Table 2 . Detailed analysis for each genome pair is shown in Figure 2 and Supplementary Figures S1-S2. There was insufficient evidence to warrant interpretation for seven sample pairs because of low genome quality. For seven additional pairs, there were one to several changes of allele frequency indicative at best of a shifting balance of quasi-species, and thus no evidence for reinfection. For four pairs, there was strong evidence for no reinfection as both genomes were of high quality, yet no differences were found. Three of these cases had a Ct <30 for the reinfection swab, indicating All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249731 doi: medRxiv preprint persistent active infection ( Table 1) . Two of these cases were reported earlier as part of a case report documenting the existence of prolonged infections [32] . Meanwhile, for one pair, there were few changes of allele frequency offering supporting evidence for reinfection. For four other pairs, there were multiple clear changes of allele frequency indicating strong evidence for reinfection. One of the latter pairs also documented the presence of the D614G mutation (23403bp A>G) at the reinfection swab-a variant that has progressively replaced the original D614 form [33, 34] . In summary, for the 16 cases where viral genome sequencing evidence was available, five cases were confirmed as reinfections, a confirmation rate of 31.3%. This confirmation rate was similar to that found in our earlier study of reinfection among those with a PCR-confirmed infection at 33.3% [5] . Applying the confirmation rate obtained through viral genome sequencing yielded a risk of documented reinfection of 0.10% (95% confidence interval (CI): 0.08-0.11%)-that is 31.3% of 129 reinfections in the cohort of 42,272 anti-SARS-CoV-2 positive persons with an antibodypositive test ≥14 days from end-of-study censoring. The incidence rate of documented reinfection was estimated at 0.66 per 10,000 person-weeks (95% CI: 0.56-0.78). That is 31.3% of 129 reinfection events in a follow-up person-time of 610,832.5 person-weeks. Figure 3 shows the incidence rate of documented reinfection versus month of follow-up in this cohort of antibody-positive persons. There was evidence for a decreasing trend in the incidence All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. rate of reinfection with each additional month of follow-up (Mantel-Haenszel trend analysis pvalue: <0.001). The results provide concrete evidence for the presence of reinfection in some individuals with detectable antibodies for SARS-CoV-2 infection, even in some with high antibody titers (Table 1 ). However, the risk of documented reinfection was rare, at ~1 per 1,000 infected persons, at least for a few months after the first antibody-positive test. There was also no evidence that antibody-positive persons experienced any waning of protective immunity over time, as the incidence rate of reinfection versus month of follow-up did not show an increasing trend over seven months following the first antibody-positive test (Figure 3 ). To the contrary, there was a trend of decreasing incidence rate, possibly explained by the (very) slowly declining incidence rate in the wider population of Qatar over the last six months [15, 35] , or possibly by strengthening of protective immunity due to repeated exposures that did not lead to established infection. Notably, a recent study from Qatar indicated an association between higher antibody titers and repeated exposures to the virus [17] . Further follow up of this cohort of antibodypositive persons over time may allow a more long-term assessment of the persistence of protection against reinfection. Remarkably, the incidence rate of reinfection found here for those with antibody-confirmed infection at ~1 per 10,000 person-weeks is very similar to that found for those with PCRconfirmed infection, as reported in our earlier reinfection study [5] . This suggests that these two populations are functionally similar. Evidence of exposure to SARS-CoV-2, regardless of the biomarker used to assess infection, appears sufficient to indicate protection against reinfection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. These findings are striking, as the epidemic in Qatar has been intense, with half of the population estimated to have acquired this infection at some point since its introduction into Qatar early in 2020 [14] [15] [16] [17] 35] . It is highly probable that a proportion of the population has been repeatedly exposed to SARS-CoV-2, but such re-exposures did not lead to more than a limited number of documentable reinfections. Other lines of evidence also support a low frequency of reinfection. The epidemic in Qatar grew rapidly and declined rapidly [15, 35] , consistent with a susceptibleinfected-recovered "SIR" epidemic dynamic in which infection elicits strong immunity against reinfection. No second wave has materialized since the epidemic peaked in May of 2020, despite easing of most restrictions [15, 35] . A recent study on health care workers in the United Kingdom also indicated lower incidence of infection in those antibody-positive [36] , and a study of immunological memory in a cohort of COVID-19 patients indicated durability of the immune response for at least 6-8 months [37] . An indirect outcome of this study is a provisional estimate of the efficacy of natural infection against reinfection. The average incidence rate of SARS-CoV-2 infection in the population of Qatar (throughout the epidemic until the end of 2020) has been estimated using mathematical modeling at ~150 per 10,000 person-weeks [15] . With the incidence rate of reinfection assessed here and in our earlier reinfection study at ~1 per 10,000 person-weeks [5] , the efficacy of natural infection against documented reinfection is estimated at While this efficacy is estimated only against documented reinfection, it is possible to extend this estimate to factor undocumented reinfections. A nationwide population-based survey in Qatar found that only 9.3% (95% CI: 7.9-11.0%) of antibody-positive persons had a prior documented PCR-confirmed infection [14] , suggesting that undocumented reinfections are perhaps ten-fold All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [18, 19] . While one reinfection was severe, none were critical or fatal and a large proportion of reinfections were minimally symptomatic (if not asymptomatic) to the extent that they were discovered only incidentally, such as through contact tracing or random testing campaigns/surveys ( Table 1 ). The severity of reinfection was also less than that of primary infection. These findings suggest that reinfections (when they rarely occur) appear well tolerated and no more symptomatic than primary infections. This study has some limitations. By study design, primary infection was indirectly ascertained through serological testing, thereby including only a subset with documented PCR-confirmed primary infections. Having said so, serological testing was based on a high-quality, validated platform, the Roche platform, one of the best available and most extensively used and investigated commercial platforms, with a specificity of at least 99.8% [38, 39] . Thus, it is unlikely that misclassified antibody-positives could have biased our findings. Viral genome sequencing analysis was possible for only a subset of reinfections, either because primary infection was only identified through antibody testing with no record of earlier PCR testing, or because the reinfection swab could not be retrieved. Reinfections were confirmed by noting differences in the viral genome between the primary infection and the reinfection. While not likely, it is theoretically possible that these differences may have occurred due to within-host evolution of the virus, as in the context of a prolonged infection [32, 40] . The potential effect of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249731 doi: medRxiv preprint these limitations is likely an overestimation, rather than underestimation, of the incidence of reinfection, thereby affirming the conclusion of the rarity of reinfections. In conclusion, SARS-CoV-2 reinfection was investigated in a large cohort of antibody-positive individuals who were followed for as long as 35 weeks. While the study documented some reinfections, they constitute a rare phenomenon, with natural infection eliciting protection against reinfection with an efficacy >90%. This points to development of robust immunity following primary infection, which lasts for at least seven months. These findings may suggest that prioritizing vaccination for those who are antibody-negative, as long as doses of the vaccine remain in short supply, could enhance the health, societal, and economic gains attained by vaccination. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. LJA conceived and designed the study and led the statistical analyses. HC contributed to study design, performed the data analyses, and wrote the first draft of the article. JAM led the viral genome sequencing analyses and AAA, YAM, and SY conducted these analyses. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. We declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249731 doi: medRxiv preprint Box 1. Classification of suspected cases of SARS-CoV-2 reinfection based on the strength of supporting epidemiological evidence. Suspected cases of SARS-CoV-2 reinfection: All antibody-positive persons with at least one PCR-positive swab that occurred ≥14 days after the first-positive antibody test. Good evidence for reinfection: Individuals who had a PCR-positive swab with a Ct value ≤30 at least 14 days after the first-positive antibody test and who had not had a PCR-positive swab within the 45 days preceding the reinfection swab. Some evidence for reinfection: Individuals who had a PCR-positive swab with a Ct value >30 at least 14 days after the first-positive antibody test and who had not had a PCR-positive swab within the 45 days preceding the reinfection swab. Weak evidence for reinfection: Individuals who had a PCR-positive swab at least 14 days after the first-positive antibody test, but who had one or more PCR-positive swabs within the 45 days preceding the reinfection swab. Ct, cycle threshold; PCR, polymerase chain reaction. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; Figure 1 . Flow chart describing the selection process of suspected cases of SARS-CoV-2 reinfection and summarizing the results of their reinfection status' evaluation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 . Results of reinfection confirmation using viral genome sequencing. Viral genome sequencing was conducted only for a subset of cases with good or some evidence of reinfection, that is, whenever paired samples of the first-infection PCR-positive swab and the reinfection PCR-positive swab were available. Indication upon comparing each genome pair N Insufficient evidence to warrant interpretation One or two genomes of low quality 7 No evidence for reinfection One change of allele frequency 1 Shifting balance of quasi-species with no evidence for reinfection Few changes of allele frequency but not sufficiently indicative of reinfection 6 Strong evidence for no reinfection Both genomes of high quality yet no significant differences found 4 * Supporting evidence for reinfection Few changes of allele frequency indicative of reinfection 1 Strong evidence for reinfection Multiple changes of allele frequency indicative of reinfection 4 Total 23 PCR, polymerase chain reaction. * Viral genome sequencing for two patients was performed as part of an earlier study assessing the risk of SARS-CoV-2 reinfection in the cohort of PCR-confirmed infected persons in Qatar [5] . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. -m 50 -n 2. Only paired reads with minimum length of 50bp were retained for analysis. The latter filtered reads were aligned to SARS-CoV-2 reference genome (NC_045512) using BWA-MEM [2] . FGBIO (v1.3.0) was subsequently used to remove PCR primer sequences from the resulting BAM file. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.15.21249731 doi: medRxiv preprint WHO Director-General's opening remarks at the media briefing on COVID-19 -11 How two tests can help contain COVID-19 and revive the economy A third of the global population is on coronavirus lockdown The socio-economic implications of the coronavirus pandemic (COVID-19): A review Assessment of the risk of SARS-CoV-2 reinfection in an intense reexposure setting Genomic evidence for reinfection with SARS-CoV-2: a case study COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America Planning and Statistics Authority-State of Qatar, The Simplified Census of Population, Housing & Establishments Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil National SARS-CoV-2 PCR testing, infection severity, and hospitalization database. 2020. 22. World Health Organization, Clinical management of COVID-19 World Health Organization, International guidelines for certification and classification (coding) of COVID-19 as cause of death High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads. medRxiv Interpreting Diagnostic Tests for SARS-CoV-2 Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2 Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study Explainer: South Korean findings suggest 'reinfected' coronavirus cases are false positives Ministry of Interior-State of Qatar, Population distribution by sex, age, and nationality: results of Kashef database Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark Cutadapt removes adapter sequences from high-throughput sequencing reads Fast and accurate short read alignment with Burrows-Wheeler transform VarScan: variant detection in massively parallel sequencing of individual and pooled samples The Sequence Alignment/Map format and SAMtools Assessment of the risk of SARS-CoV-2 reinfection in an intense reexposure setting The light blue color highlights reinfection cases that were confirmed by viral genome sequencing. * Average PCR Ct value over different targets for SARS-CoV-2 genes and/or proteins. † The category "individual request" refers to testing conducted at a healthcare facility based on the individual's request, often because of some requirement for testing, such as for travel. ‡ The category "port of entry" refers to testing conducted at the border or airport upon return from travel. § The category "clinical suspicion" refers to testing conducted at a healthcare facility based on presence of signs or symptoms, or reported history of exposure. ** The category "survey" refers to surveillance random PCR testing campaigns conducted in workplaces and residential areas. † † The reason for the swab in the hospital record was "clinical suspicion", but no further details were provided and the person was reported to have no COVID-19 symptoms.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.